Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.
Cagrilintide-semaglutide significantly reduced bodyweight in adults with obesity compared to placebo, but the clinical implications of these findings require further investigation.
Where it sits
this study against the rest of the cagrilintide (am833) corpusSummary and findings
The study measured the efficacy and safety of cagrilintide-semaglutide at doses of 1.7 mg and 1.0 mg in adults with obesity or overweight. Participants receiving cagrilintide-semaglutide experienced significant bodyweight reductions compared to placebo. Adverse events were common but mostly mild or moderate.
Abstract
<h4>Background</h4>Cagrilintide-semaglutide (CagriSema) 2·4 mg each has shown clinically meaningful bodyweight reductions in global phase 3 studies. Different dosing options might support individual treatment responses and tolerability. We aimed to investigate the efficacy and safety of once per week subcutaneous cagrilintide-semaglutide 1·7 mg each or 1·0 mg each versus placebo in participants with obesity or overweight and at least one obesity-related complication.<h4>Methods</h4>This multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial (REDEFINE 9) was conducted across 24 sites in Canada, France, Germany, the UK, and the USA. Eligible participants were adults aged 18 years or older; with a BMI of at least 30 kg/m<sup>2</sup> or at least 27 kg/m<sup>2</sup> and one or more obesity-related complication; and without diabetes. Participants were randomly assigned (2:1:2:1) centrally, using block randomisation (block size of six) and a web-based system, to receive cagrilintide 1·7 mg plus semaglutide 1·7 mg (hereafter cagrilintide-semaglutide 1·7 mg each, starting at 0·25 mg each and escalated over 12 weeks), placebo 1·7 mg plus 1·7 mg (hereafter placebo 1·7 mg each), cagrilintide 1·0 mg plus semaglutide 1·0 mg (hereafter cagrilintide-semaglutide 1·0 mg each, starting at 0·25 mg each and escalated over 8 weeks), or placebo 1·0 mg plus 1·0 mg (hereafter placebo 1·0 mg each) for 68 weeks, plus nutrition and physical activity counselling until week 74. All treatments were administered subcutaneously once per week. The coprimary endpoints were relative mean change in bodyweight from baseline to week 68 and proportion of participants reaching a bodyweight reduction of at least 5% at week 68, assessed in the full analysis set (defined as all randomly assigned participants). Safety was assessed in the safety analysis set (defined as all randomly assigned participants who received at least one dose of the study drug). This study is registered with ClinicalTrials.gov, NCT06388187 (completed).<h4>Findings</h4>From June 24 to Oct 30, 2024, 333 participants were assessed for eligibility and 24 were excluded. 309 participants were randomly assigned (full analysis set: 104 assigned to cagrilintide-semaglutide 1·7 mg each, 103 to cagrilintide-semaglutide 1·0 mg each, and 102 to pooled placebo). 308 participants received at least one dose of the study drug. 291 (94%) of 309 participants completed the study and 254 (82%) were on treatment at week 68. The mean age was 48·0 years (SD 13·6) and mean BMI was 39·1 kg/m<sup>2</sup> (6·8). 239 (77%) participants were female, and 70 (23%) were male. For the efficacy estimand, the mean relative change from baseline in bodyweight at week 68 was -20·7% (SE 0·9) with cagrilintide-semaglutide 1·7 mg each, -21·0% (1·0) with cagrilintide-semaglutide 1·0 mg each, and -2·0% (1·0) with the pooled placebo. Bodyweight reductions were significantly greater with both doses of cagrilintide-semaglutide than with placebo (estimated treatment difference [ETD] -18·8 percentage points [95% CI -21·5 to -16·0]; p<0·0001 for the 1·7 mg each dose and -19·0 percentage points [-21·8 to -16·2]; p<0·0001 for the 1·0 mg each dose). The proportion of participants reaching bodyweight reductions of at least 5% at week 68 was significantly greater with cagrilintide-semaglutide than with placebo (95·1% [SE 2·7] with the 1·7 mg each dose vs 33·4% [5·6] with placebo, ETD 61·7 percentage points [95% CI 49·5-74·0], p<0·0001; and 96·3% [2·2] with the 1·0 mg each dose, ETD 63·0 percentage points [51·1-74·9], p<0·0001). Adverse events were reported in 102 (99%) of 103 participants receiving cagrilintide-semaglutide 1·7 mg each, 98 (95%) of 103 receiving cagrilintide-semaglutide 1·0 mg each, and 93 (91%) of 102 receiving the placebo. Most adverse events were mild or moderate and gastrointestinal-related. No deaths were reported.<h4>Interpretation</h4>Cagrilintide-semaglutide at 1·7 mg each and 1·0 mg each was superior to placebo at reducing bodyweight in adults with overweight or obesity, suggesting that different dose levels might support treatment flexibility.<h4>Funding</h4>Novo Nordisk.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.